Schizophrenia/Psychosis

"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."

The experts weighed in on a wide variety of psychiatric issues for the January 2023 issue of Psychiatric Times.

Are you ready to understand how recovery-oriented cognitive therapy (CT-R) promotes wellness and empowerment for individuals experiencing serious mental health challenges? Check out this CME article.

From a new FDA approval to treating “New Year depression” in patients, here are highlights from the week in Psychiatric Times.

New approval for schizophrenia and bipolar I disorder.

From rare copy number variants in treatment-resistant psychosis to the psychiatric response to human trafficking, here are highlights from the week in Psychiatric Times.

Genetic testing for severe psychosis? Researchers investigated rare disease-associated copy number variants in patients with treatment-resistant schizophrenia.

“We will open the book. Its pages are blank. We are going to put words on them ourselves. The book is called Opportunity and its first chapter is New Year’s Day.”

From the effects of caffeine on smokers with schizophrenia and bipolar disorder to the initiation of a trial for a new ADHD medication, here are highlights from the week in Psychiatric Times.

The ongoing study demonstrated statistically significant improvements over baseline in comparison to results at 6 weeks.

We remain challenged to improve treatments and outcomes in schizophrenia. Explore the latest options.

Smoking and drinking (caffeine): Researchers analyzed caffeine intake and levels in smokers with schizophrenia and bipolar disorder.

VR-based training may help improve social cognition and functioning in patients with schizophrenia.

Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.

Psychiatric Times looks back on the major research on schizophrenia from 2022.

Clozapine for catatonia? Researchers performed a systematic review of the evidence as a treatment for catatonia.

Does research support the efficacy of NAC for negative symptoms in clozapine-resistant patients with schizophrenia?

The first patient in a phase 2/3 study evaluating ulotaront for MDD has been enrolled.

The phase 3 SERENITY III trial investigating at-home use of dexmedetomidine (BXCL501) sublingual film for agitation associated with bipolar I or II disorder or schizophrenia has started.

From the cross-cultural dimensions of psychosis to the economic burden of schizophrenia, here are highlights from the week in Psychiatric Times.

All medical students, psychiatry residents, fellows, faculty at academic medical institutions, and psychiatrists in independent practice must develop skills in cultural competence to avoid perpetuating disparities in health outcomes for BIPOC individuals with serious mental illnesses.

$chizophrenia: Researchers estimated the economic burden of schizophrenia in the United States.

Experts share the benefits of motivational interviewing when working with this patient population—and how clinicians can incorporate it into their practice.

What is the impact of antipsychotic side effects on medication adherence?

Individuals with a psychotic disorder are 2.5 times more likely than those without one to develop dementia.

Herbal medicines have been used to treat mental health disorders since ancient times, and continue to be useful today.

What is the effect of cannabis use on adherence to medications in patients with psychosis?

From ketamine response to differences between mTBI and concussion, here are highlights from the week in Psychiatric Times.

Will it hurt my baby? Researchers investigated associations between first trimester exposure to second-generation antipsychotics and major congenital malformations.

The FDA has accepted the NDA for aripiprazole 2-month, ready-to-use, long-acting injectable.